Summary of Use during Lactation

No information is available on the clinical use of inotuzumab oxogamicin during breastfeeding. Because inotuzumab oxogamicin is a large protein molecule with a molecular weight of 168,000 Da and its active metabolite is 97% plasma protein bound, the amount in milk is likely to be very low. However, the half-life of inotuzumab oxogamicin is about 12.3 days and it might accumulate in the infant. Until more data become available, inotuzumab oxogamicin should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during inotuzumab oxogamicin therapy for at least 2 months after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Inotuzumab Ozogamicin

CAS Registry Number

635715-01-4

Drug Class

Breast Feeding

Lactation

Antibodies, Monoclonal, Humanized

Antineoplastic Agents